These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 39387560)
1. An integrative analysis based on multiple cell death patterns identifies an immunosuppressive subtype and establishes a prognostic signature in lower-grade glioma. Lian H; Wang J; Yan S; Chen K; Jin L Ann Med; 2024 Dec; 56(1):2412831. PubMed ID: 39387560 [TBL] [Abstract][Full Text] [Related]
2. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP Front Immunol; 2022; 13():933973. PubMed ID: 36045691 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma. Xu S; Tang L; Liu Z; Luo C; Cheng Q Front Immunol; 2021; 12():731048. PubMed ID: 34659218 [TBL] [Abstract][Full Text] [Related]
4. A cuproptosis-based prognostic model for predicting survival in low-grade glioma. Zhao Z; Ma Y; Liu Y; Chen Z; Zheng J Aging (Albany NY); 2024 May; 16(10):8697-8716. PubMed ID: 38738989 [TBL] [Abstract][Full Text] [Related]
5. Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma. Yu H; Gong M; Qi J; Zhao C; Niu W; Sun S; Li S; Hong B; Qian J; Wang H; Chen X; Fang Z BMC Cancer; 2022 Aug; 22(1):885. PubMed ID: 35964070 [TBL] [Abstract][Full Text] [Related]
6. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics. Lin WW; Ou GY; Zhao WJ J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473 [TBL] [Abstract][Full Text] [Related]
7. Cuproptosis-related gene-located DNA methylation in lower-grade glioma: Prognosis and tumor microenvironment. Zhu L; Yuan F; Wang X; Zhu R; Guo W Cancer Biomark; 2024; 40(2):185-198. PubMed ID: 38578883 [TBL] [Abstract][Full Text] [Related]
8. A disulfidptosis-associated long noncoding RNA signature to predict low-grade glioma classification, prognosis, tumor microenvironment, and therapy regimens: Observational study. Qin X; Chen Z; Wu L; Ding R Medicine (Baltimore); 2024 Aug; 103(34):e39316. PubMed ID: 39183405 [TBL] [Abstract][Full Text] [Related]
9. Identification and clinical validation of diverse cell-death patterns-associated prognostic features among low-grade gliomas. Yang W; Yu H; Lei Q; Pu C; Guo Y; Lin L Sci Rep; 2024 May; 14(1):11874. PubMed ID: 38789729 [TBL] [Abstract][Full Text] [Related]
10. Identification and verification of the ferroptosis- and pyroptosis-associated prognostic signature for low-grade glioma. Wang J; Ren J; Liu J; Zhang L; Yuan Q; Dong B Bosn J Basic Med Sci; 2022 Sep; 22(5):728-750. PubMed ID: 35276059 [TBL] [Abstract][Full Text] [Related]
11. Elucidating the Role of Pyroptosis in Lower-Grade Glioma: Development of a Novel Scoring System to Enhance Personalized Therapeutic Approaches. Chen X; Xu Y; Wang M; Ren C J Mol Neurosci; 2023 Aug; 73(7-8):649-663. PubMed ID: 37566191 [TBL] [Abstract][Full Text] [Related]
12. Identification and validation of anoikis-related genes to clarify the prognosis and immune mechanisms of patients with low-grade glioma. Wang J; Liu Y; Qian M; Xu W; Chen J; Deng Y; Luo R; Chen J; Jia W; Liu L; Tian C Biochem Biophys Res Commun; 2024 Jun; 711():149894. PubMed ID: 38603834 [TBL] [Abstract][Full Text] [Related]
13. Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma. Li J; Guo Q; Xing R BMC Cancer; 2023 Aug; 23(1):727. PubMed ID: 37543576 [TBL] [Abstract][Full Text] [Related]
14. TGF-β Score based on Zhang W; Yan Z; Zhao F; He Q; Xu H Recent Pat Anticancer Drug Discov; 2024; 19(5):610-621. PubMed ID: 37718518 [TBL] [Abstract][Full Text] [Related]
15. An integrative multi-omics analysis based on liquid-liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature. Zheng J; Wu Z; Qiu Y; Wang X; Jiang X J Transl Med; 2022 Jan; 20(1):55. PubMed ID: 35093128 [TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of necroptosis related gene signature to predict clinical outcomes, immune status and drug sensitivity in lower grade Glioma. Hu X; Ma Y; Xia Y; Liu B Heliyon; 2024 Jan; 10(1):e23947. PubMed ID: 38192784 [TBL] [Abstract][Full Text] [Related]
17. Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of Liu Z; Yang L; Xie Z; Yu H; Gu T; Shi D; Cai N; Zhuo S Oncol Res; 2024; 32(5):965-981. PubMed ID: 38686055 [TBL] [Abstract][Full Text] [Related]
18. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data. Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666 [TBL] [Abstract][Full Text] [Related]
19. Stemness subtypes in lower-grade glioma with prognostic biomarkers, tumor microenvironment, and treatment response. Ye S; Yang B; Yang L; Wei W; Fu M; Yan Y; Wang B; Li X; Liang C; Zhao W Sci Rep; 2024 Jun; 14(1):14758. PubMed ID: 38926605 [TBL] [Abstract][Full Text] [Related]
20. Identification of DNA methylation-regulated WEE1 with potential implications in prognosis and immunotherapy for low-grade glioma. Zhong WJ; Zhang LZ; Yue F; Yuan L; Zhang Q; Li X; Lin L Cancer Biomark; 2024; 40(3-4):297-317. PubMed ID: 39213054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]